Tarsus Pharmaceuticals, Inc.
TARSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Tarsus Pharmaceuticals, Inc. focuses on Biotechnology services and products. Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. At a $2.61B market cap, Tarsus Pharmaceuticals, Inc. ranks as a mid-cap company within healthcare. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites.
Market Cap
$2.61B
Beta
0.50
P/E (TTM)
—
P/E (Fwd)
36.05
EPS (TTM)
$-1.15
EPS (Fwd)
$1.66
ROE
-14.0%
ROA
-5.9%
Cash
$388.7M
Total Debt
$88.7M
Free CF
-$21.3M
52W Change
38.4%
Annual Financials
Cash vs Debt
Tarsus Pharmaceuticals, Inc. holds $388.7M in cash against $88.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$21.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -14.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $25.8M (2022) to $451.4M (2025), reflecting a 1648% increase over the period.
The relatively low beta of 0.50 suggests TARS is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, TARS has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Tarsus Pharmaceuticals, Inc.'s trajectory.